Canaccord analyst William Plovanic raised the firm’s price target on Edwards Lifesciences to $76 from $68 and keeps a Hold rating on the shares. The analyst said he continues to stay on the sidelines until the company can show some meaningful improvement in TAVR, or until the TMTT business becomes sizable enough to offset the stagnation in TAVR.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on EW:
- EDWARDS LIFESCIENCES REPORTS FOURTH QUARTER RESULTS
- Edwards Lifesciences sees Q1 adjusted EPS 58c-64c, consensus 59c
- Edwards Lifesciences backs FY23 adjusted EPS $2.45-$2.60, consensus $2.50
- Edwards Lifesciences reports Q4 adjusted EPS 64c, consensus 61c
- Edwards Lifesciences options imply 5.3% move in share price post-earnings
